Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.315 EUR -1.1% Market Closed
Market Cap: 36.3m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Gensight Biologics SA
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Gensight Biologics SA
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Gensight Biologics SA
PAR:SIGHT
Accounts Receivables
€35k
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Accounts Receivables
€30.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Accounts Receivables
€61.5m
CAGR 3-Years
380%
CAGR 5-Years
83%
CAGR 10-Years
90%
Inventiva SA
PAR:IVA
Accounts Receivables
€809k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Accounts Receivables
€27m
CAGR 3-Years
-15%
CAGR 5-Years
11%
CAGR 10-Years
17%
OSE Immunotherapeutics SA
PAR:OSE
Accounts Receivables
€5m
CAGR 3-Years
89%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

Gensight Biologics SA
Glance View

Market Cap
36.3m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
0.171 EUR
Overvaluation 46%
Intrinsic Value
Price

See Also

What is Gensight Biologics SA's Accounts Receivables?
Accounts Receivables
35k EUR

Based on the financial report for Jun 30, 2024, Gensight Biologics SA's Accounts Receivables amounts to 35k EUR.

What is Gensight Biologics SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
-75%

Over the last year, the Accounts Receivables growth was -13%. The average annual Accounts Receivables growth rates for Gensight Biologics SA have been -75% over the past three years .

Back to Top